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Kehllee L. Popovich, NP, Angela C. Davis, RN, Elizabeth Staunton, NP, Hiram G. Bezerra, MD, PHD,
Alan Markowitz, MD, Daniel I. Simon, MD, Marco A. Costa, MD, PHD, Basar Sareyyupoglu, MDA 66-year-old woman with severe mitral ste-nosis (mean gradient, 13.81 mm Hg; valvearea, 0.8 cm2) and extensive mitral annular
calciﬁcation (MAC) presented with New York Heart
Association functional class IV congestive heart fail-
ure. Balloon mitral valvuloplasty was not considered
due to the high Wilkins score (i.e., 12) Because of a
Society of Thoracic Surgeons mortality score of
10.04% and cirrhosis (Child-Pugh B), the heart team
deemed her at prohibitive surgical risk. We, there-
fore, decided to perform a transapical transcatheter
mitral valve implantation using a SAPIEN XT valve
(Edwards Lifesciences, Irvine, California). Cardiac
computed tomography (CCT) performed as part of
the procedural planning revealed heterogeneous
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17-mm axial distribution, the maximal area perpen-
dicular to the MAC centerline was 4.0 cm2
(Figure 1). Across that area, a virtual valve was simu-
lated in 3 different sizes, 23, 26, and 29 mm, using
advanced post-processing software (3mensio Version
7.2, Pie Medical, Maastricht, the Netherlands) to
help, along with the maximal area and calcium
distribution, determine the optimal valve sizing
and positioning (i.e., achieving the best sealing while
minimizing the risk of valve embolization) (Figure 2).
We, therefore, selected a 26-mm valve (w30% over-
sizing) aiming at positioning it 60% ventricular and
40% atrial (i.e., in line with the MAC distribution)
(Figures 2G and 2H). Although severe MAC can be
clearly visualized on ﬂuoroscopy, using it as a singlen Heart and Vascular Institute, University Hospitals
nic, Edwards Lifesciences, and St. Jude Medical; and
advisory board for Medtronic. Dr. Costa has a rela-
lationships relevant to the contents of this paper to
FIGURE 1 MAC Morphology and Functional Assessment
(A) Pre-procedural transesophageal echocardiogram showing severe mitral stenosis. (B) Pre-procedural 3-dimensional volume-rendered cardiac computed
tomography (CCT) demonstrating, in a double oblique plane, C-shaped MAC distributed more posteriorly (detailed in the yellow square). (C) A more
ventricular axial distribution of MAC is revealed (17 mm, white line between the 2 yellow dots); the red line corresponds to the maximal area (4.0 cm2)
across the MAC, which is demonstrated as a cross section (D). MAC ¼ mitral annulus calciﬁcation.
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FIGURE 2 Device Sizing and Positioning
On pre-procedural cardiac computed tomography (CCT), a virtual valve is simulated in 3 different sizes (23, 26, and 29 mm) and assessed in
2- (top row) and 3- (bottom row) dimensional images across the maximal area for optimal device sizing and positioning. (A and B) A 23-mm valve
implant simulation reveals suboptimal sealing (light red area). The simulation of a 26-mm valve shows optimal sealing (C and D), whereas the
29-mm valve implant simulation appears to be excessively large (E and F). We, therefore, simulated a 26-mm valve implanted 40% atrially
(above the green line) and 60% ventricularly (below the green line), in line with mitral annulus calciﬁcation distribution (G and H).
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1524landmark could be potentially imprecise in this proce-
dure due to its broad axial distribution. Hence, be-
sides the best angiographic view (i.e., perpendicular
to the perpendicular cross-sectional planes through
the centerline of the MAC), the course of the left
circumﬂex (LCX) artery was depicted to serve as an
additional landmark, taking advantage of its anatomic
proximity to the mitral valve annulus (Figure 3C to 3F).
To help locate the optimal surgical access in the best
angiographic views, a virtual catheter was simulated
from the access site to the left atrium through the cen-
ter of the MAC. A 3-dimensional volume rendering
demonstrated that the most coaxial position to the
MAC could be achieved by accessing the sixthintercostal space, lateral to the apex (Figures 3A
to 3C). The ﬂuoroscopy images were comparable
to the ones predicted by CCT, and the valve was suc-
cessfully deployed in the intended position (mean
gradient, 5.08 mm Hg) with a trace of paravalvular
leak (Figures 3G and 3H). This case demonstrates the
usefulness of CCT for procedural planning in the com-
plex scenario of a native mitral valve interven-
tion. Notably, the post-processing capabilities of CCT
provided, in addition to valve sizing information,
optimal access route and valve positioning, ultimately
contributing to procedural success. Further investiga-
tion is warranted to better elucidate the role of trans-
catheter valve therapies in this setting.
FIGURE 3 Access Site, Deployment Position, and Final Result
Three-dimensional volume-rendered (A) and maximal intensity projection (B) images of the left chest wall with the simulated catheter crossing
the center of the mitral annulus calciﬁcation (MAC) determine the access through the sixth intercostal space more lateral from the apex
(blue asterisk) to obtain a more coaxial position. (C) In a simulated angiography best view, the course of the left circumﬂex coronary (LCx)
is depicted (top curved white dashed line) to be used as a landmark during the procedure. The catheter (yellow solid line) is simulated as it
passes through the center of the MAC (white line). (D) Intraprocedural ﬂuoroscopy demonstrated a comparable course of the LCx (curved
dotted red line) in relation to the MAC (dotted white line). Valve positioning (E) and deployment (F) in a more ventricular location were
accomplished using the LCx course as an additional landmark. (G) Post-implantation transesophageal echocardiogram showed a mean gradient
of 5 mm Hg and a trace paravalvular leak. Optimal results in terms of valve expansion and position are revealed by ﬂuoroscopy (H) and
post-procedural cardiac computed tomography (I).
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